Kanjinti is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC):...as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease….Kanjinti should only be used in patients with metastatic or early breast cancer whose tumours have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.

Kanjinti is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC):...in combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable....in combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease….in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin….in combination with neoadjuvant chemotherapy followed by adjuvant KANJINTI therapy, for locally advanced (including inflammatory) disease or tumours > 2 cm in diameter....Kanjinti should only be used in patients with metastatic or early breast cancer whose tumours have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.

Eligible women were aged 18 years or older, had histologically confirmed HER2-positive invasive early breast cancer...725 were randomly assigned to receive ABP 980 (n=364) or trastuzumab (n=361)….Pathological complete response was recorded in 172 (48%, 95% CI 43–53) of 358 patients in the ABP 980 group and 137 (41%, 35–46) of 338 in the trastuzumab group (risk difference 7·3%, 90% CI 1·2–13·4; RR 1·188, 90% CI 1·033–1·366)...